Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DAWN Stock Price Chart Interactive Chart >
DAWN Price/Volume Stats
|Current price||$5.72||52-week high||$28.70|
|Prev. close||$5.75||52-week low||$5.44|
|Day high||$5.80||Avg. volume||246,137|
|50-day MA||$9.25||Dividend yield||N/A|
|200-day MA||$16.77||Market Cap||354.14M|
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Most Popular Stories View All
DAWN Latest News Stream
|Loading, please wait...|
DAWN Latest Social Stream
View Full DAWN Social Stream
Latest DAWN News From Around the Web
Below are the latest news stories about Day One Biopharmaceuticals Inc that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Day One...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET. A live audio webcast of the presentation will b
The world now has one less Coachella music festival. Goldenvoice, the event production company behind the Coachella Valley Music & Arts Festival, filed a trademark-infringement lawsuit against Live Nation Entertainment in Los Angeles federal court over a New Year's Eve live music event called Coachella Day One 22. Now a judge has ordered a temporary restraining order, and ordered Live Nation to stop promoting the New Year's event under its original name on Ticketmaster, according to Deadline.
Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Major Shareholder Sells $1,989,394.14 in Stock
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) major shareholder Pharmaceutical Co Ltd Takeda sold 110,338 shares of the businesss stock in a transaction dated Wednesday, December 8th. The stock was sold at an average price of $18.03, for a total value of $1,989,394.14. The sale was disclosed in a filing with the SEC, which is available through 
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) was up 6.5% on Thursday . The stock traded as high as $19.70 and last traded at $19.15. Approximately 6,242 shares traded hands during trading, a decline of 95% from the average daily volume of 117,350 shares. The stock had previously closed at $17.98. Separately, Zacks Investment Research cut Day 
DAWN Price Returns